Lasa Supergenerics Limited LASA.NS Open Lasa Supergenerics Limited in new tab
Lasa Supergenerics Limited Analysis (LASA.NS)
Is Lasa Supergenerics Limited a good investment? Lasa Supergenerics Limited (LASA.NS) is currently trading at 7.98 INR.
In terms of valuation, the stock trades at a P/E ratio of 2.09. This relatively low multiple may signal that Lasa Supergenerics Limited is undervalued compared to historical market norms.
Earnings Schedule: Lasa Supergenerics Limited is expected to release its next earnings report on May 25, 2026.
Investor FAQ
Does Lasa Supergenerics Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Lasa Supergenerics Limited?
Lasa Supergenerics Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 25, 2026. The company currently has a trailing EPS of 3.70.
Company Profile
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2022 | 0.25 INR |
| Sept. 16, 2022 | 0.2500 |
| 2021 | 0.25 INR |
| Sept. 15, 2021 | 0.2500 |
Yearly aggregated dividends
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion